Xencor Past Earnings Performance
Past criteria checks 0/6
Xencor's earnings have been declining at an average annual rate of -37.8%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 2.6% per year.
Key information
-37.8%
Earnings growth rate
-36.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 2.6% |
Return on equity | -28.0% |
Net Margin | -232.8% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up
Dec 03Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 10Xencor: Vudalimab Development Along With Hidden Gem Candidate
Sep 12Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up
Sep 12Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Sep 06Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?
Jul 13Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S
Jun 16Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Mar 27There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Feb 27Xencor: Standing Out With XmAb Technology
Feb 03Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
Jan 05Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
Nov 13Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
Nov 10Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Aug 08Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon
Aug 12Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M
Aug 03Xencor: Capital-Efficient Platform Tech Play With A Lot Going On
Jun 03Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate
Feb 18Revenue & Expenses Breakdown
How Xencor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 85 | -198 | 60 | 0 |
30 Jun 24 | 134 | -177 | 58 | 0 |
31 Mar 24 | 162 | -133 | 52 | 0 |
31 Dec 23 | 168 | -126 | 52 | 0 |
30 Sep 23 | 145 | -119 | 49 | 0 |
30 Jun 23 | 113 | -128 | 49 | 0 |
31 Mar 23 | 98 | -140 | 49 | 0 |
31 Dec 22 | 165 | -55 | 46 | 0 |
30 Sep 22 | 297 | 30 | 45 | 0 |
30 Jun 22 | 289 | 22 | 43 | 0 |
31 Mar 22 | 327 | 109 | 41 | 0 |
31 Dec 21 | 275 | 83 | 39 | 0 |
30 Sep 21 | 163 | -4 | 35 | 0 |
30 Jun 21 | 179 | 24 | 32 | 0 |
31 Mar 21 | 124 | -64 | 30 | 0 |
31 Dec 20 | 123 | -69 | 30 | 0 |
30 Sep 20 | 84 | -83 | 29 | 0 |
30 Jun 20 | 71 | -80 | 27 | 0 |
31 Mar 20 | 77 | -61 | 26 | 0 |
31 Dec 19 | 157 | 27 | 24 | 0 |
30 Sep 19 | 165 | 36 | 23 | 0 |
30 Jun 19 | 172 | 49 | 24 | 0 |
31 Mar 19 | 153 | 39 | 23 | 0 |
31 Dec 18 | 41 | -70 | 22 | 0 |
30 Sep 18 | 59 | -45 | 21 | 0 |
30 Jun 18 | 30 | -71 | 18 | 0 |
31 Mar 18 | 43 | -53 | 17 | 0 |
31 Dec 17 | 46 | -38 | 17 | 0 |
30 Sep 17 | 22 | -55 | 16 | 0 |
30 Jun 17 | 30 | -40 | 15 | 0 |
31 Mar 17 | 84 | 15 | 14 | 0 |
31 Dec 16 | 109 | 45 | 13 | 0 |
30 Sep 16 | 103 | 40 | 12 | 0 |
30 Jun 16 | 99 | 38 | 12 | 0 |
31 Mar 16 | 34 | -18 | 12 | 0 |
31 Dec 15 | 28 | -18 | 11 | 0 |
30 Sep 15 | 12 | -27 | 10 | 0 |
30 Jun 15 | 9 | -23 | 9 | 0 |
31 Mar 15 | 9 | -19 | 8 | 0 |
31 Dec 14 | 10 | -16 | 7 | 0 |
30 Sep 14 | 6 | -19 | 4 | 0 |
30 Jun 14 | 8 | -17 | 3 | 0 |
31 Mar 14 | 11 | 85 | 2 | 0 |
31 Dec 13 | 10 | 85 | 3 | 0 |
Quality Earnings: XNCR is currently unprofitable.
Growing Profit Margin: XNCR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XNCR is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.
Accelerating Growth: Unable to compare XNCR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XNCR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: XNCR has a negative Return on Equity (-27.98%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 02:23 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xencor, Inc. is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Peter Lawson | Barclays |
Zhiqiang Shu | Berenberg |
Etzer Darout | BMO Capital Markets Equity Research |